Stop the pain! A nation-wide quality improvement programme in paediatric oncology pain control

Boris Zernikow1, Carola Hasan, Tanja Hechler

  • 1Vodafone Foundation Institute for Children's Pain Therapy and Paediatric Palliative Care, Children's Hospital Datteln, Witten/Herdecke University, Dr. Friedrich Steiner Str. 5, D-45711 Datteln, Germany. Boris.Zernikow@t-online.de

Insights

The Schmerz-Therapie in der Onkologischen Paediatrie (STOP) project improved pain management in pediatric oncology through active quality improvement strategies. While healthcare professionals

Area of Science:

  • Pediatric Oncology
  • Pain Management
  • Quality Improvement

Background:

  • Limited understanding of translating pain management guidelines into pediatric oncology care.
  • Initiation of the Schmerz-Therapie in der Onkologischen Paediatrie (STOP) study, a nationwide pediatric quality improvement initiative.

Purpose of the Study:

  • To enhance pediatric oncology pain control in Germany.
  • To assess the impact of the STOP project on pain management quality.
  • To compare outcomes between active and non-active quality management departments.

Main Methods:

  • Longitudinal, multi-center study involving German pediatric oncology departments.
  • Four hypotheses tested regarding healthcare professional knowledge, active participation impact, patient/parent perspectives, and knowledge differences between active/non-active departments.
  • Data collection via surveys, interviews, and standardized pain control documentation; intervention included educational materials and active participation feedback.

Main Results:

  • All healthcare professionals showed increased knowledge in pain management after three years.
  • Actively participating departments demonstrated objective improvements in pain control, including reduced painful drug administration and decreased pain ratings.
  • Healthcare professionals perceived earlier and more appropriate pain therapy initiation, though patients and parents did not report perceived quality improvement.

Conclusions:

  • The STOP project successfully improved structural, process, and outcome quality in pediatric oncology pain management.
  • Discrepancies between professional self-assessment and patient/parent perspectives suggest potential limitations in measurement tools or the magnitude of improvement perceived by patients.
Abstract

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...